[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577128":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":31,"responsibleParty":46,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants receiving lisocabtagene maraleucel treatment",null,[12],"Biological: Lisocabtagene maraleucel",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"BIOLOGICAL","Lisocabtagene maraleucel","As per product label",[9],[20],{"name":21,"affiliation":21,"role":22},"Bristol-Myers Squibb","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"CIBMTR","RECRUITING","Milwaukee","Wisconsin","53226","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-87.90647,43.0389,{"lat":44,"lon":43},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100577128",false,"NCT06794268","A Study to Patients With Relapsed\u002FRefractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting","Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed\u002FRefractory Follicular Lymphoma in the Postmarketing Setting","Inclusion Criteria:\n\n• Participants must have been treated in the post-marketing setting with at least 1 infusion of lisocabtagene maraleucel (liso-cel) used for the treatment of relapsed\u002Frefractory (R\u002FR) follicular lymphoma (FL), including FL Grade 1, Grade 2 and Grade 3a, within the FDA-approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA\n\nExclusion Criteria:\n\n* Participants known to be participating in investigational studies at the time of liso-cel, infusion\n* Participants treated with liso-cel for the treatment of R\u002FR FL Grade 3b\n* Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product","ALL","18 Years",{"count":57,"type":58},300,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities",[62],"Follicular Lymphoma",[62],"2025-02-21",{"date":66,"type":67},"2025-02-24","ACTUAL",{"date":69,"type":67},"2025-02-04",{"date":71,"type":58},"2044-08-31",{"name":5,"class":6},1]